Binding activity and immunogenic characterization of recombinant C-terminal quarter and half of the heavy chain of botulinum neurotoxin serotype A

Human Vaccines

Volumn 7, Issue 10, 2011, Pages 1090-1095

  Yu, Yun Zhou ^a   Ma, Yao ^a   Chen, Yan Xia ^a   Gong, Zheng Wei ^a   Wang, Shuang ^a   Yu, Wei Yuan ^a   Sun, Zhi Wei ^a  

^a AIR FORCE GENERAL HOSPITAL   (China)

Author keywords

Binding activity; Botulinum neurotoxin; Domain; Ganglioside; Immunogenity; Receptor; Vaccine

Indexed keywords

BOTULINUM TOXIN A; CARBOXY TERMINAL HALF OF HEAVY CHAIN OF BOTULINUM TOXIN A; CARBOXY TERMINAL QUARTER OF HEAVY CHAIN OF BOTULINUM TOXIN A; GANGLIOSIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; BOTULINUM ANTISERUM; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENCY; ESCHERICHIA COLI; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; PROTEIN BINDING;

ANIMALS; ANTIBODIES, BACTERIAL; BOTULINUM ANTITOXIN; BOTULINUM TOXINS, TYPE A; ESCHERICHIA COLI; FEMALE; GANGLIOSIDES; GENE EXPRESSION; MICE; MICE, INBRED BALB C; PROTEIN BINDING; RECOMBINANT PROTEINS;

EID: 80054742938     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.10.16763     Document Type: Article

References (38)

1. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rew 2000; 80:717- 66.
2. Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxtins: structure, function and therapeutic utility. Trends Biochem Sci 2002; 27:552-8. (Pubitemid 35335403)
3. Kozaki S, Kamata Y, Watarai S, Nishiki T, Mochida S. Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb Pathog 1998; 25:91-9. (Pubitemid 28398979)
4. Ginalski K, Venclovas C, Lesyng B, Fidelis K. Structure-based sequence alignment for the beta-trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site. FEBS Lett 2000; 482:119-24.
5. Rummel A, Mahrhold S, Bigalke H, Binz T. The Hccdomain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 2004; 51:631-43. (Pubitemid 38233933)
6. Sharma S, Zhou Y, Singh BR. Cloning, expression and purification of C-terminal quarter of the heavy chain of botulinum neurotoxin type A. Protein Expr Purif 2006; 45:288-95. (Pubitemid 43120433)
7. Chen R, Shi J, Cai K, Tu W, Hou X, Liu H, et al. Improved soluble expression and characterization of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli by using a PCR-synthesized gene and a Trx co-expression strain. Protein Expr Purif 2010; 71:79-84.
8. Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie 2000; 82:955-66.
9. Middlebrook JL. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Adv Drug Deliv Rev 2005; 57:1415-23. (Pubitemid 40791119)
10. Smith LA, Rusnak JM. Botulinum neurotoxin vaccines: past, present and future. Crit Rev Immunol 2007; 27:303-18.
11. Rusnak JM, Smith LA. Botulinum neurotoxin vaccines: Past history and recent developments. Hum Vaccin 2009; 5:794-805.
12. Aoki KR, Smith LA, Atassi MZ. Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. Crit Rev Immunol 2010; 30:167-87.
13. Gao YL, Gao S, Kang L, Nie C, Wang JL. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen. Hum Vaccin 2009; 6:462-6.
14. Staats HF, Fielhauer JR, Thompson AL, Tripp AA, Sobel AE, Maddaloni M, et al. Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. PLoS One 2011; 6:16532.
15. Atassi MZ, Dolimbek BZ, Deitiker P, Jankovic J, Aoki KR. A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit 2007; 20:15-21. (Pubitemid 46160156)
16. Zhang P, Ray R, Singh BR, Li D, Adler M, Ray P. An efficient drug delivery vehicle for botulism countermeasure. BMC Pharmacol 2009; 9:12.
17. Evans ER, Skipper PJ, Shone CC. An assay for botulinum toxin types A, B and F that requires both functional binding and catalytic activities within the neurotoxin. J Appl Microbiol 2009; 107:1384-91.
18. Behrensdorf-Nicol HA, Bonifas U, Kegel B, Silberbach K, Kramer B, Weisser K. In vitro determination of tetanus toxicity by an endopeptidase assay linked to a ganglioside-binding step. Toxicol In Vitro 2010; 24:988-94.
19. Tavallaie M, Chenal A, Gillet D, Pereira Y, Manich M, Gibert M, et al. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett 2004; 572:299-306. (Pubitemid 39092553)
20. Mansour AA, Mousavi SL, Rasooli I, Nazarian S, Amani J, Farhadi N. Cloning, high level expression and immunogenicity of 1,163-1,256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E. Biologicals 2010; 38:260-4.
21. Simpson LL, Maksymowych AB, Kiyatkin N. Botulinum toxin as a carrier for oral vaccines. CMLS 1999; 56:47-61. (Pubitemid 29471924)
22. Padua RA, Larghero J, Robin M, le Pogam C, Schlageter MH, Muszlak S, et al. PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 2003; 9:1413-7. (Pubitemid 37466192)
23. Bongat AF, Saksena R, Adamo R, Fujimoto Y, Shiokawa Z, Peterson DC, et al. Multimeric bivalent immunogens from recombinant tetanus toxin HC fragment, synthetic hexasaccharides and a glycopeptide adjuvant. Glycoconj J 2010; 27:69-77.
24. Rummel A, Eichner T, Weil T, Karnath T, Gutcaits A, Mahrhold S, et al. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc Natl Acad Sci USA 2007; 104:359-64. (Pubitemid 46068036)
25. Montecucco C, Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 1995; 8:423-72. (Pubitemid 26015975)
26. Lalli G, Herreros J, Osborne SL, Montecucco C, Rossetto O, Schiavo G. Functional characterisation of tetanus and botulinum neurotoxins binding domains. J Cell Sci 1999; 112:2715-24. (Pubitemid 29429794)
27. Singh BR. Intimate details of the most poisonous poison. Nat Struct Biol 2000; 7:617-9. (Pubitemid 30636667)
28. Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, et al. Subunit vaccine against the seven serotypes of botulism. Infect Immun 2008; 76:1314-8. (Pubitemid 351428096)
29. Maruta T, Dolimbek BZ, Aoki KR, Atassi MZ. Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: a new assay for blocking and non-blocking antibodies. J Neurosci Methods 2006; 151:90-6. (Pubitemid 43294431)
30. Jin R, Rummel A, Binz T, Brunger AT. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 2006; 444:1092-5. (Pubitemid 46018531)
31. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312:592-6.
32. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 2006; 580:2011-4.
33. Yu YZ, Sun ZW, Wang S, Yu WY. High-level expression of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen. Chin J Biotech 2007; 23:812-7.
34. Yu YZ, Zhang SM, Ma Y, Zhu HQ, Wang WB, Du Y, et al. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F. Clin Immunol 2010; 137:271-80.
35. Yu YZ, Sun ZW, Li N, Wang S, Wang RL, Yu WY. Protection with a recombinant Hc of Clostridium botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine. Immunopharmacol Immunotoxicol 2009; 31:261-6.
36. Yu YZ, Li N, Zhu HQ, Wang RL, Du Y, Wang S, et al. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 2009; 27:2816-22.
37. Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 1998; 66:4817-22. (Pubitemid 28453087)
38. Zhou Y, Singh BR. Cloning, high level expression, single step purification and binding activity of His6- tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain. Protein Expr Purif 2004; 34:8-16. (Pubitemid 38272309)